Advanced Biomed Inc. Announces Launch of A+PerfusC(TM) - Integrated Perfusion 3D Cell Culture Platform for Precision Medicine and Drug Discovery
MWN-AI** Summary
Advanced Biomed Inc. (Nasdaq: ADVB), a biotechnology firm dedicated to innovative biomedical solutions for precision medicine, has officially launched its A+PerfusC™ system, a state-of-the-art integrated perfusion 3D cell culture platform. Announced on September 19, 2025, this compact incubator is designed to simulate human physiological conditions, thereby enhancing drug discovery and precision medicine research.
The A+PerfusC™ system allows for up to 12 days of continuous, hands-free cell culture, while reducing the risk of human error and contamination. This technology promotes the formation of spheroids and organoids, pivotal for understanding cellular behavior and improving drug response predictability. Notably, it supports up to 600 tumor spheroids per row and can be easily transferred into 96 or 384-well plates for high-throughput drug screening.
Advanced Biomed's innovative platform is characterized by automated nutrient delivery and waste clearance, alleviating stress on cells and enhancing viability. Dr. Yi Lu, CEO of the company, emphasized that this system addresses critical limitations seen in traditional static cell cultures, which often result in uneven nutrient distribution and metabolic waste accumulation.
The global 3D cell culture market is projected to grow significantly, from USD 2.32 billion in 2025 to over USD 4.71 billion by 2030, with a CAGR of more than 15.6%, indicating strong market potential for Advanced Biomed's new offerings. The applications for A+PerfusC™ are diverse, including personalized oncology research, regenerative medicine, and organoid studies.
Advanced Biomed Inc. continues to strive for regulatory clearances and aims for global expansion, as it develops advanced circulating tumor cell detection technologies. For further details, visit the company's website at www.advanbiomed.com.
MWN-AI** Analysis
Advanced Biomed Inc. (Nasdaq: ADVB) has made a significant stride in the biotechnology sector with the launch of its A+PerfusC™ integrated perfusion 3D cell culture platform. This innovation addresses critical limitations in traditional static cell culture by ensuring consistent nutrient delivery and waste clearance, thereby promoting cell viability and more effectively modeling human physiological conditions.
The global 3D cell culture market is currently experiencing robust growth, estimated at USD 2.32 billion in 2025 and projected to reach over USD 4.71 billion by 2030, indicating a compound annual growth rate (CAGR) of 15.6%. Advanced Biomed’s entry into this market with a unique and validated product positions it favorably against competitors.
Investors should consider both the immediate and long-term implications of this launch on ADVB’s stock performance. If the company successfully transitions to mass production and meets regulatory standards, the anticipated demand in personalized oncology research, regenerative medicine, and drug discovery could drive substantial revenue growth. The capacity for high-throughput drug screening and the system's adaptability further enhance its market attractiveness.
However, potential investors must remain aware of inherent risks, including the competitive landscape in biotech, regulatory hurdles, and market variability. As stated, forward-looking statements from the company underscore uncertainties that may affect actual performance.
In light of these developments, ADVB shares should be watched closely. As a long-term investment proposition, the growth trajectory in the 3D cell culture market coupled with Advanced Biomed’s innovative platform suggests a promising outlook, provided the company navigates commercialization successfully. Investors might benefit from a cautious yet optimistic approach, weighing both the risks and opportunities presented by this launch. Regular updates on product development and market penetration will be crucial indicators for making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
[Tainan City], Taiwan, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (Nasdaq: ADVB) (the “Company”, “Advanced Biomed”), a biotechnology company focused on developing and commercializing innovative biomedical products for precision medicine and advanced diagnostics, today announced the launch of its A+PerfusC ™ system, a compact, all?in?one perfusion 3D cell culture incubator designed to replicate human physiological conditions in vitro.
(A+PerfusC ™ 3D System-a perfusion-based 3D cell culture in a compact incubator)
The A+PerfusC ™ platform integrates automated perfusion with environmental control in a compact format that can be mounted directly onto a microscope for real?time observation. The system supports up to 12 days of continuous, hands?free culture, reducing the risk of human error and contamination. By maintaining uniform nutrient delivery and preventing waste accumulation, the platform promotes spheroid and organoid formation, enhancing cell viability, growth, and drug response predictability. The system is characterized and proved by:
- 8 independent channel/patient source per plate
- 600 tumor spheroids per row for one patient
- 4,800 tumor spheroids per plate
- Easy to transfer into 96 or 384 well plate for high-throughput drug screening
- Easy to mount on microscopy platforms
- Expandable- control platform supporting up to four incubators. (undergoing)
A+PerfusC ™ system and its 3D culture plate (consumable) have passed internal testing and validation with design finalized. Currently the Company is advancing its mass-production development. Its commercialization can be achieved following mass-production development finalized and quality control standards established.
Potential applications include personalized oncology research, invitro drug screening, regenerative medicine, organoid studies, and stem cell research. According to Mordor Intelligence, the global 3D cell culture market was valued at USD 2.32 billion in 2025 and is projected to exceed USD 4.71 billion by 2030, representing a compound annual growth rate of over 15.6% (source: https://www.mordorintelligence.com/industry-reports/3d-cell-culture-market ) .
Dr. Yi Lu, CEO of the Company, commented: “Traditional static cell culture often leads to uneven nutrient delivery and waste buildup, compromising cell growth, viability, and reproducibility. Notably, in certain high-density culture scenarios, particularly within multi-microwell 3D culture devices, metabolic waste can rapidly accumulate inside the micro-grooves, requiring more frequent medium replacement which can be labor-intensive to preserve culture quality.”
“Our 3D culture system evenly delivers nutrients and clears waste, reducing cellular stress, boosting long-term viability, and more accurately mimicking human tissue complexity for improved drug response and disease modeling.”
“The Company plans to scale up the A+PerfusC ™ system for high?throughput use and integrate imaging with AI?driven analytics, aiming to accelerate tumor profiling, refine cell therapy protocols, and advance personalized treatment development.”
About Advanced Biomed Inc.
Advanced Biomed Inc. is a Nevada?incorporated holding company specializing in innovative biomedical technologies for cancer detection and precision medicine.
Operating through subsidiaries in Taiwan, Hong Kong, and Mainland China, the Company has developed a proprietary microfluidic platform that integrates semiconductor and biotechnology to enable advanced circulating tumor cell (CTC) detection, enrichment, and analysis. Its portfolio includes devices, biochips, and designed for cancer screening, diagnosis, treatment selection, and prognosis assessment, with regulatory clearances in progress in China and plans for future global expansion.
For more information, please visit: www.advanbiomed.com .
Forward ? Looking Statements
This press release contains forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may, “will, “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the “Risk Factors” section of the registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov . The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
For more information, please contact:
Advanced Biomed Inc.
Steven I-Fang Cheng
Email: info@advbiomedicine.com
invest@advbiomedicine.com
FAQ**
How does Advanced Biomed Inc. ADVB plan to differentiate its A+PerfusC™ system from existing 3D cell culture technologies in the market?
What specific regulatory approvals does Advanced Biomed Inc. ADVB anticipate obtaining for the A+PerfusC™ system, and how will this impact its commercialization timeline?
Considering the projected growth of the cell culture market, what market share does Advanced Biomed Inc. ADVB aim to capture with its A+PerfusC™ system within the first few years post-launch?
How does Advanced Biomed Inc. ADVB intend to integrate AI-driven analytics into the A+PerfusC™ system, and what benefits will this bring to personalized oncology research and drug development?
**MWN-AI FAQ is based on asking OpenAI questions about Advanced Biomed Inc. (NASDAQ: ADVB).
NASDAQ: ADVB
ADVB Trading
-0.35% G/L:
$4.305 Last:
4,480 Volume:
$4.27 Open:
